Analyst consensus rating
Arcus Biosciences Analyst Rating: Strong Buy
RCUS is rated Strong Buy by 12 analysts with a $38.33 target. As of 2026-08-23.
Direct answer
Arcus Biosciences's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $38.33.
Forecast evidence checked August 23, 2026.
Get free Arcus Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $30.34
- Average price target
- $38.33
- High price target
- $47.00
- Low price target
- $23.00
- Low target gap
- -24.2%
- Target upside
- +26.3%
- High target gap
- +54.9%
- Target range width
- 79.1%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Arcus Biosciences?
Arcus Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $38.33.
How far are Arcus Biosciences's low and high targets from the recorded price?
The low target implies -24.2%, while the high target implies +54.9%.
How many analysts are included in Arcus Biosciences's consensus?
The verified consensus includes 12 analysts.
How is Arcus Biosciences's target upside or downside calculated?
The average target of $38.33 is divided by the recorded price of $30.34, then one is subtracted to produce +26.3%. This does not guarantee a future return.
When was Arcus Biosciences's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.